Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients

Background Immunotherapy for patients with microsatellite‐instable (MSI‐H) tumors or BRAF ‐inhibitors combination treatment for BRAF‐ mutated (mut BRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these molecular changes in trial patients are low. Unselected population‐based studies of these molecular changes are warranted. Methods A population‐based cohort of 798 mCRC patients in Scandinavia was studied....